The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Genes, BRCA1

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Genes, BRCA1.
Connection Strength

10.337
  1. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
    View in: PubMed
    Score: 0.452
  2. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer. 2011 Jun 13; 11:246.
    View in: PubMed
    Score: 0.360
  3. Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy? J Clin Oncol. 2011 May 01; 29(13):1652-4.
    View in: PubMed
    Score: 0.355
  4. Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010 Feb; 194(2):309-10.
    View in: PubMed
    Score: 0.328
  5. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat. 2010 Apr; 120(3):593-601.
    View in: PubMed
    Score: 0.312
  6. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
    View in: PubMed
    Score: 0.306
  7. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
    View in: PubMed
    Score: 0.296
  8. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
    View in: PubMed
    Score: 0.287
  9. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA. 2007 Dec 26; 298(24):2910-1.
    View in: PubMed
    Score: 0.283
  10. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007 Dec; 7(12):937-48.
    View in: PubMed
    Score: 0.282
  11. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005 Dec 01; 65(23):10692-9.
    View in: PubMed
    Score: 0.245
  12. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
    View in: PubMed
    Score: 0.243
  13. Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients. J Med Genet. 2005 Mar; 42(3):276-81.
    View in: PubMed
    Score: 0.233
  14. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004 Jan-Feb; 10 Suppl 1:S5-9.
    View in: PubMed
    Score: 0.215
  15. Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol. 2003 Sep 01; 21(17):3191-3.
    View in: PubMed
    Score: 0.208
  16. Breast cancer genetics in African Americans. Cancer. 2003 Jan 01; 97(1 Suppl):236-45.
    View in: PubMed
    Score: 0.201
  17. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002 Mar 01; 62(5):1481-8.
    View in: PubMed
    Score: 0.189
  18. Cancer genetics in oncology practice. Ann Oncol. 2001 Jul; 12(7):895-908.
    View in: PubMed
    Score: 0.181
  19. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001 Jun 28; 344(26):2028-9.
    View in: PubMed
    Score: 0.181
  20. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
    View in: PubMed
    Score: 0.157
  21. Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
    View in: PubMed
    Score: 0.148
  22. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Jun; 169(3):561-571.
    View in: PubMed
    Score: 0.143
  23. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.137
  24. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet. 1997 May; 60(5):1233-6.
    View in: PubMed
    Score: 0.135
  25. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
    View in: PubMed
    Score: 0.135
  26. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016 11 11; 18(1):112.
    View in: PubMed
    Score: 0.131
  27. Genetics in clinical cancer care--the future is now. N Engl J Med. 1996 Nov 07; 335(19):1455-6.
    View in: PubMed
    Score: 0.131
  28. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134.
    View in: PubMed
    Score: 0.131
  29. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Oct; 95(40):e4975.
    View in: PubMed
    Score: 0.130
  30. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016; 11(7):e0158801.
    View in: PubMed
    Score: 0.128
  31. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
    View in: PubMed
    Score: 0.125
  32. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.117
  33. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
    View in: PubMed
    Score: 0.115
  34. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
    View in: PubMed
    Score: 0.114
  35. Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res. 2014; 16(4):424.
    View in: PubMed
    Score: 0.112
  36. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul; 146(2):421-7.
    View in: PubMed
    Score: 0.111
  37. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013 Nov; 142(1):177-85.
    View in: PubMed
    Score: 0.106
  38. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013 Feb; 138(1):273-9.
    View in: PubMed
    Score: 0.101
  39. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1362-70.
    View in: PubMed
    Score: 0.097
  40. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
    View in: PubMed
    Score: 0.095
  41. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
    View in: PubMed
    Score: 0.094
  42. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2011; 13(6):R110.
    View in: PubMed
    Score: 0.092
  43. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
    View in: PubMed
    Score: 0.091
  44. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1690-702.
    View in: PubMed
    Score: 0.090
  45. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
    View in: PubMed
    Score: 0.089
  46. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
    View in: PubMed
    Score: 0.085
  47. Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
    View in: PubMed
    Score: 0.084
  48. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009 Feb; 18(2):200-8.
    View in: PubMed
    Score: 0.076
  49. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009; 11(5):R76.
    View in: PubMed
    Score: 0.076
  50. MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008 Oct; 8(10):1689-98.
    View in: PubMed
    Score: 0.075
  51. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr; 82(4):937-48.
    View in: PubMed
    Score: 0.072
  52. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
    View in: PubMed
    Score: 0.072
  53. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
    View in: PubMed
    Score: 0.069
  54. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1416-21.
    View in: PubMed
    Score: 0.068
  55. Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns. 2006 Aug; 15(4):267-76.
    View in: PubMed
    Score: 0.064
  56. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
    View in: PubMed
    Score: 0.063
  57. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43.
    View in: PubMed
    Score: 0.063
  58. Using genetic analysis to individualize preventive measures for breast and ovarian cancers. Nat Clin Pract Oncol. 2006 Apr; 3(4):182-3.
    View in: PubMed
    Score: 0.063
  59. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9.
    View in: PubMed
    Score: 0.062
  60. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20; 117(6):988-91.
    View in: PubMed
    Score: 0.062
  61. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10.
    View in: PubMed
    Score: 0.061
  62. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005 Aug; 16(6):667-74.
    View in: PubMed
    Score: 0.060
  63. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1534-8.
    View in: PubMed
    Score: 0.059
  64. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
    View in: PubMed
    Score: 0.058
  65. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15; 22(12):2328-35.
    View in: PubMed
    Score: 0.055
  66. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
    View in: PubMed
    Score: 0.054
  67. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
    View in: PubMed
    Score: 0.054
  68. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Sep; 201(2):257-264.
    View in: PubMed
    Score: 0.052
  69. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
    View in: PubMed
    Score: 0.050
  70. BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet. 2002 Sep; 71(3):625-31.
    View in: PubMed
    Score: 0.049
  71. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51.
    View in: PubMed
    Score: 0.048
  72. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22.
    View in: PubMed
    Score: 0.048
  73. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8.
    View in: PubMed
    Score: 0.046
  74. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
    View in: PubMed
    Score: 0.043
  75. Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer. 2000 Feb; 82(3):705-11.
    View in: PubMed
    Score: 0.041
  76. Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: feature selection. Med Phys. 2000 Jan; 27(1):4-12.
    View in: PubMed
    Score: 0.041
  77. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999 Nov 27; 354(9193):1846-50.
    View in: PubMed
    Score: 0.040
  78. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999 Sep 01; 91(17):1475-9.
    View in: PubMed
    Score: 0.040
  79. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
    View in: PubMed
    Score: 0.037
  80. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.031
  81. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012 Jun; 133(3):865-80.
    View in: PubMed
    Score: 0.023
  82. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008 Jul 22; 99(2):371-4.
    View in: PubMed
    Score: 0.018
  83. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
    View in: PubMed
    Score: 0.017
  84. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
    View in: PubMed
    Score: 0.016
  85. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006; 8(2):R15.
    View in: PubMed
    Score: 0.016
  86. Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys. 2004 Mar; 31(3):549-55.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.